Crisis & Risk Communication Consultant
The difference between Corporate Crisis and Emergency Risk Communications.
Experiences from the field - Epidemic/Pandemic Risk Communication in practice.
The synergies between Corporate Crisis and Emergency Risk Communications.
During & Post COVID19 Risk Communication - What's next?
Senior Director, PwC Cyber, Forensic & Privacy
Professor, VU University
Examples of crises (COVID-19, investigations by authorities
Crises you could have prevented (preventive fraud measures)
Leadership in crisis
How best to act
Never waste a good crisis
The aftermath of a crisis: emerge stronger
We are not out of the woods of this crisis yet, a lot remains to be known yet
Opportunities for conversations for important change will emerge. It does not guarantee change, however
Real estate will restructure itself regardless. The office market will lose its historical attractiveness
AI and the IoT will receive an important boost
In the short term, the extent of the economic damage will depend on how well governments are able to manage the health crisis, particularly coming out from the lockdown.
Economist - Private Sector Development and Investment, The World Bank Group
Cascading effects of demand-cum-supply shocks operating on international businesses
Estimates of adverse effects – supply chains, output, employment, business performance.
Areas of government support
Supply Chain & Operations Expert,
Ex- Novo Nordisk
Short overview of our company setup to enable understanding of the context
3 key pillars we distinguish (strategic, standard operational & crisis operational or BCP activities)
Prioritising or sequencing or both? Why and how? - The decision making process
Resources and unique solutions
Lessons to learn from the hiccups surfacing and how to funnel them into the key focus areas for improvement
Director, Healthcare & Life Sciences
Public-private partnerships for healthcare – the legacy trends
what’s needed most now for the pandemic
What the future of such collaborations is going to look like
Global Supply Chain Lead - European Distributor Markets, Pfizer
Supply Chain Challenges in Pharma confronting the pandemic
The problem of stockpiling
Leadership at the time of COVID19
Learning from the crisis and future-proofing
Founder & CEO – Chrome Data Analytics & Media
Cascading effects of COVID19
Uncertainties of the pandemic
Long term impacts
Senior Product Development Specialist - Market Intelligence (Healthcare)
The Economist Intelligence Unit
Introduction to Digital Therapeutics
Current market landscape of Digital Therapeutics
FDA's guidance on Software as a Medical Device
How digital therapeutics will improve overall clinical outcomes by disrupting the value chain?
Improving compliance and adherence with digital therapeutics